Analysis of the prevalence of drug-resistant hepatitis B virus in patients with antiviral therapy failure in a Chinese tertiary referral liver centre (2010-2014).

@article{Meng2017AnalysisOT,
  title={Analysis of the prevalence of drug-resistant hepatitis B virus in patients with antiviral therapy failure in a Chinese tertiary referral liver centre (2010-2014).},
  author={Tian Meng and Xiaofeng Shi and Xuyang Gong and H. Deng and Yao Huang and X. Shan and Youlan Shan and A. Huang and Quanxin Long},
  journal={Journal of global antimicrobial resistance},
  year={2017},
  volume={8},
  pages={
          74-81
        }
}
OBJECTIVES To study the prevalence of drug-resistant HBV in patients with therapy failure in a Chinese tertiary referral liver centre. METHODS 1223 HBV-infected patients who underwent genotypic resistance testing between 2010-2014 were studied. RESULTS 3TC genotypic resistance was the most common (46.5%), followed by LdT resistant (46.2%), ETV intermediate (37.9%), ADV resistant (11.4%), TDF intermediate (11.4%) and ETV resistant (1.7%). The 3TC resistance rate increased from 39.8% in 2010… Expand
Evolution of drug-resistant mutations in HBV genomes in patients with treatment failure during the past seven years (2010–2016)
TLDR
Analysis of HBV-infected patients who underwent HBV polymerase gene mutation test from 2010 to 2016 found that NA-related mutations in HBV RT region increased in the past seven years, especially for LAM, and frequency of rtL180M and rtA181T/V increased gradually during the pastSeven years. Expand
Evaluation of drug resistance mutations in patients with chronic hepatitis B
TLDR
No remarkable resistance to ETV and TDF were found in this study, but the high rate of the probable TDF resistance was striking, with 3.14%. Expand
A systematic review of hepatitis B virus (HBV) drug and vaccine escape mutations in Africa: A call for urgent action
TLDR
Overall, there is an urgent need for improved diagnostic screening, enhanced laboratory assessment of HBV before and during therapy, and sustained roll out of tenofovir in preference to lamivudine alone. Expand
A systematic review of Hepatitis B virus (HBV) drug and vaccine escape mutations in Africa: a call for urgent action
TLDR
There is an urgent need for improved diagnostic screening, enhanced laboratory assessment of HBV before and during therapy, and sustained roll out of tenofovir in preference to lamivudine alone. Expand
Global prevalence and phylogeny of hepatitis B virus (HBV) drug and vaccine resistance mutations
TLDR
Phylogenetic analysis suggested that RAM/VEMs can arise independently of treatment/vaccine exposure, and screening for genotype and for resistance‐associated mutations may help to improve stratified patient treatment. Expand
Global prevalence and phylogeny of hepatitis B virus (HBV) drug and vaccine resistance mutations
TLDR
HBV RAMs/VEMs have been found globally and across genotypes, with the highest prevalence observed in genotype C variants, and evidence that polymorphisms associated with drug and vaccine resistance may have been present in the mid 20th century is shown. Expand
Hepatitis B virus resistance to tenofovir: fact or fiction? A systematic literature review and structural analysis of drug resistance mechanisms [version 1; peer review: 1 approved]
Background: Tenofovir (TFV) is a widely used treatment for chronic hepatitis B virus (HBV) infection. There is a high genetic barrier to the selection of TFV resistance-associated mutations (RAMs),Expand
Hepatitis B virus resistance to tenofovir: fact or fiction? A systematic literature review and structural analysis of drug resistance mechanisms [version 1; peer review: awaiting peer review]
Background: Tenofovir (TFV) is a widely used treatment for chronic hepatitis B virus (HBV) infection. There is a high genetic barrier to the selection of TFV resistance-associated mutations (RAMs),Expand
Hepatitis B virus resistance to tenofovir: fact or fiction? A systematic literature review and structural analysis of drug resistance mechanisms
TLDR
There is emerging evidence for polymorphisms that may reduce susceptibility to TVF, however, good correlation between viral sequence and treatment outcomes is currently lacking and further studies are essential to optimise individual treatment and public health approaches. Expand
Hepatitis B virus resistance to tenofovir: fact or fiction? A synthesis of the evidence to date
TLDR
There is emerging evidence for polymorphisms that reduce susceptibility to TVF, and a better understanding of HBV drug resistance is imperative to ensure that these do not impact on the international elimination targets that are to be met by 2030. Expand
...
1
2
...

References

SHOWING 1-10 OF 27 REFERENCES
Combined Analysis of the Prevalence of Drug-Resistant Hepatitis B Virus in Antiviral Therapy-Experienced Patients in Europe (CAPRE).
TLDR
These findings support resistance testing in cases of apparent NA therapy failure and highlight the impact of exposure to lamivudine and adefovir on development of drug resistance and cross-resistance. Expand
Genotypic resistance profile of hepatitis B virus (HBV) in a large cohort of nucleos(t)ide analogue‐experienced Chinese patients with chronic HBV infection
TLDR
The results provide new information on HBV genotypic resistance profiles in a large cohort of Chinese patients with chronic HBV infection and may have important clinical implication for HBV drug resistance management in China. Expand
Epidemiology study of HBV genotypes and antiviral drug resistance in multi-ethnic regions from Western China
TLDR
HBV genotypes and resistance-conferring mutations had different geographic and demographic distributions in Western China, which provided molecular epidemiology data for clinical management. Expand
Long‐term monitoring shows hepatitis B virus resistance to entecavir in nucleoside‐naïve patients is rare through 5 years of therapy
TLDR
Long‐term monitoring showed low rates of resistance in nucleoside‐naïve patients during 5 years of ETV therapy, corresponding with potent viral suppression and a high genetic barrier to resistance, support ETV as a primary therapy that enables prolonged treatment with potentiral suppression and minimal resistance. Expand
Emergence of hepatitis B virus quasispecies with lower susceptibility to nucleos(t)ide analogues during lamivudine treatment.
TLDR
Lamivudine monotherapy favours the emergence of viral quasispecies that influence the response rate to adefovir rescue therapy independently from baseline viraemia and lower the susceptibility to other nucleos(t)ide analogues. Expand
Distribution and Hepatocellular Carcinoma–Related Viral Properties of Hepatitis B Virus Genotypes in Mainland China: A Community-Based Study
TLDR
HBV subgenotypes B2, C1, and C2 are endemic in Mainland China and HBV genotype C exhibits less replication activity in the young and harbors higher frequencies of the HCC-associated mutations than genotype B. Expand
Hepatitis B Virus (HBV) Subgenotypes C2 and B2 Differ in Lamivudine- and Adefovir-Resistance-Associated Mutational Patterns in HBV-Infected Chinese Patients
TLDR
HBV/C2 and HBV/B2, two prevalent subgenotypes, differ in lamivudine- and adefovir-resistance-associated mutational patterns and are more likely to have disease progression than HBV /C2-infected patients. Expand
[Efficacy of adefovir dipivoxil was not related to genotypes B and C of hepatitis B virus: a randomized, double-blind, multicenter clinical study].
  • Hong Zhao, J. Li, +5 authors C. Si
  • Medicine
  • Zhonghua shi yan he lin chuang bing du xue za zhi = Zhonghua shiyan he linchuang bingduxue zazhi = Chinese journal of experimental and clinical virology
  • 2007
TLDR
There were no significant difference in virological and serological response to ADV therapy between patients infected with HBV genotype B and C in both treatment arms. Expand
Viral features of lamivudine resistant hepatitis B genotypes A and D
TLDR
The mutational pattern during selection of lamivudine resistant HBV strains differs between genotypes A and D, which may have consequences for a salvage regimen initiated for treatment of lamvudineresistant HBV. Expand
Hepatitis B virus genotypes B and C do not affect the antiviral response to lamivudine.
TLDR
There was no difference in the antiviral response and the rate of development of YMDD mutations in Chinese patients with genotype B and C after 1 year of lamivudine. Expand
...
1
2
3
...